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Lentiviral Vectors Come of Age? 




The pharmaceutical industry has been attracted to the gene therapy field and 
is starting to support clinical trials, establishing collaborative strategies to develop 
commercial products which in many cases are based on lentiviral vectors. The 
predictable widespread use of lentiviral vectors in next-generation gene therapy 
scenarios aimed at dealing with not only rare diseases raises important challenges 
and hurdles regarding their manufacture. The author reflects on this in the chapter 
on the state of the art in the manufacture of lentiviral vectors, addressing some 
current manufacturing processes, their achievements, and the uncertainties in 
ensuring a validated process capable of releasing consistent vector quality that 
meets global health authorities’ requirements. In summary, the proposal looks at 
the goals and challenges that must be addressed in manufacturing lentiviral vectors, 
in order to satisfy supply in the commercial stage, before we reach the next stage in 
gene therapy.
Keywords: lentiviral vector, large-scale manufacturing, gene therapy
1. Introduction
The practice of medicine is undergoing a revolution, moving from a focus on 
the treatment of symptoms, toward targeting the genetic cause of the disease. The 
huge development of disciplines, including but not restricted to molecular and 
cellular biology and genetic sciences, provides the framework for the advancement 
of individualized precision medicine. This new conception of medicine is based on 
the novel paradigm: the genes represent medicines themselves. Gene therapy is the 
groundbreaking strategy, which uses genes as medicines. Gene therapy is no longer 
an experimental approach [1, 2], and as with any novel therapy, patients’ benefits 
must be balanced against the nonzero risk of the therapeutical approach. Most 
products currently assayed in clinical trials of gene therapy are viral vectors [3], 
i.e., biological products that challenge both the manufacturing processes in order to 
guarantee the supply of adequate quantities of the active vector and the regulatory 
requirements from the medicine agencies of target countries. In summary, viral vec-
tor production on a large scale implies novel challenges for a multidisciplinary field, 
in order to accommodate such specific requirements within the industrial process.
The first gene therapy experiments took advantage of the strategy that mem-
bers of the Retroviridae family of viruses evolved to spread and remain stable in 
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the host, with the integration of their genomes. Since those experiments we have 
assisted to a fast development of the viral vector field fuelled by promising data 
raised from early studies until the achievement of the current scenario [4, 5]. 
The gene therapy field is witnessing a sort of gold rush that is boosting personal-
ized medicine by confronting many diseases as genetically treatable traits. Early 
vector developments focused on Gammaretrovirus as integrating entities for the 
delivery of a stable expression of the correctable gene, but since the last decade, 
they have been displaced by vectors deriving from the Lentivirus genus. As opposed 
to Gammaretrovirus, the Lentivirus displayed preferred integration sites in cod-
ing genomic regions rather than in transcription regulatory regions, and this has 
become a major safety feature to exploit. Nowadays, non-replicative self-inacti-
vating lentiviral (SIN) vectors are used in the vast majority of novel gene therapy 
clinical trials using integrative vectors and are considered by now the optimal tools 
for ex vivo gene therapy and the safest and easiest-to-use vectors available for the 
delivery of genes into mammalian tissues [6].
The use of retroviral vectors in gene therapy as an emerging technology is 
following the Gartner hype cycle. Hope and expectation were seen when gene 
therapy entered the clinic in the early 1990s, but due to a lack of profound success 
and the unexpected death in 2000 of two patients, caused by the treatment, the 
expectations slowed down. In the following decade (2000–2010), two approaches 
coexisted: first, follow-up and ongoing clinical trials that were using an integrative 
type of vector (gammaretroviruses, gRV) used in those clinical trials resulting 
in unexpected fatal deaths and, second, intensive academic research focused on 
the development of new viral vectors and methodical exploration of the clinical 
procedure. This resulted in the advent of a novel type of vector called SIN-LV, 
derived from the causative agent of AIDS, the Lentivirus HIV, properly modified 
and engineered to render them safer (see Vectorizing HIV). In the current decade 
(2010 to the present), we have been recording investigative clinical trials using both 
vectors in several hematological and neurodegenerative rare diseases with a conclu-
sion: the feasibility of the second-generation gene therapy approaches [4, 5]. This is 
mostly due to the huge development of SIN-LV vectors, due to their safer profile, in 
comparison with gammaretroviruses [6].
Gene therapy products have entered the commercialization phase, and a dozen 
treatments have been approved since 2012 in EU and the USA [1]. Up to last year, all 
of them were treatments for rare or ultrarare conditions, but in August 2017, a new 
key milestone for gene therapy development can be added to the chart, reinforcing 
the concept of gene therapy use in frequent pathologies in which current treat-
ments are failing: the Novartis receives the first ever FDA approval for a CAR-T cell 
therapy, Kymriah® (tisagenlecleucel), for children and young adults with B-cell 
acute lymphoid leukemia (ALL). The goals reached in the past two decades in the 
gene therapy field open novel expectations offering a cure to rare genetic diseases, 
cancer, infectious diseases, and vaccine development, and in the short-medium 
term, innovations in the field will make affordable genetic intervention covering an 
array of diseases with a gene-defined cause [7].
The aim of this review is to recapitulate specific problems related to the manu-
facture of lentiviral vectors in particular during production stages, known as the 
upstream process (USP), focusing on the limitations that exist when scaling up, 
due to the nature of the virus, the particularities of the lentivector life cycle, and 
the producer cell line commonly used for production. There are excellent reviews 
[13–16] that provide a detailed description of the methodologies that can be fol-
lowed in order to produce lentivectors on a large scale. There is a growing interest 
in the lentiviral vector field, and there are many topics worthy of a description. 
For those interested in more detailed, specific topics, i.e., manufacturing of CAR-T 
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approaches, purification strategies, or specific problems linked to the target cell, I 
recommend references [10, 11, 17].
2. Delivering genes with Lentivirus
The virus-derived vector as delivery system lies at the heart of most currently 
employed forms of gene therapy; without the viral vectors, there is no treatment. 
These viruses must be custom-made in specialized facilities for each treatment, but 
manufacturing them is costly and onerous: it requires great expertise and multidis-
ciplinary teams and specialized facilities with stringent conditions both for safety/
containment and demanding production methods, under good manufacturing 
practice with regard to compliance (GMP) [8].
Viral vectors are complex bioproducts with an ordered architecture and are very 
sensitive to handling and environmental conditions. For these reasons, there are 
stringent requirements aimed at preserving biological activity during all stages of 
the manufacturing and delivery process. Then, during the production, purification, 
storage, and transportation stages, it is necessary to maintain specific rigorous con-
trol aimed at minimizing the loss of biological activity, in addition to controls which 
are common to other bioproducts, such as sterility. This implies that the manufac-
ture of large amounts of a viral vector cannot simply be produced by transferring 
the know-how and well-stablished procedures developed in the pharmaceutical 
industry for the production of monoclonal antibodies or recombinant proteins.
The large-scale manufacture of lentivectors for use in humans is becoming 
the bottleneck in the success of ongoing or planned gene therapy development to 
be launched in the near future [9]. Indeed, the manufacturing capabilities of the 
companies to satisfy the short-medium term markets are central to decision-making 
for backers and investors, who are becoming cautious with regard to biotech firms 
developing gene therapy products that do not have a secure virus source [9]. Several 
papers have recently reported the need to succeed in developing a global manu-
facturing process for lentiviral vectors, driven by a deep understanding of both 
the product and the process, in order to establish the viral vector product profile 
and critical quality attributes [10, 11]. In addition, lentiviral products require the 
creation of a worldwide accepted and adopted international standard, suitable for 
the standardization of trials, in particular quantitation trials related to the potency 
of the target product, allowing a comparison of cross-manufacturing results for any 
lentiviral platform [12].
3. Vectorizing HIV
Human immunodeficiency virus (HIV) belongs to the family Retroviridae, 
subfamily Orthoretrovirinae, and genus Lentivirus of animal viruses. According 
to Baltimore’s classification, it is an RNA reverse-transcribing virus (group VI). 
Retroviridae members are among the more exclusive entities in the virus taxon, 
and research in the field has provided outstanding insights into key concepts 
on biology, which were the basis demonstrating that dogmas do not stand up in 
science (the central dogma on molecular biology), providing one of the most 
useful tools in molecular biology (retrotranscriptase), supporting the concept 
of the existence of genes that provoke cancer (viral oncogenes), and finally, 
demonstrating that viral-genome integration also evolved in animal viruses as an 




The HIV pandemic in the 1980s alerted humanity to the silent spreading of a 
deadly disease. HIV, a Lentivirus, was revealed to be a highly sophisticated virus 
with fine-tuned regulation, and it was mostly deciphered a decade after its discov-
ery [5]. Scientists took advantage of the impressive knowledge gained about the 
virus in a decade transforming a dangerous virus into a safe viral vector. It is worth 
mentioning that HIV was described as a new virus in 1987, and barely 10 years 
later, a safe version of HIV-derived vectors was demonstrated as efficient in animal 
models [23].
Taking advantage of the previous studies with Gammaretrovirus vectors, the 
HIV-derived vectors were engineered to contain a mere 15–20% of the original 
virus, allowing plenty of room for transgenes/regulatory sequences. A method for 
production was established, and subsequent improvements ensure that the cur-
rently available format of the third generation of self-inactivating (SIN) vector [18] 
is generated as the safest and easiest-to-use vector available. It has multipurpose 
uses, from research and preclinical studies to clinical trials as there is a commercial 
product based on this type of vector. In all cases the procedure followed for produc-
tion is almost the same, representing one of the main drawbacks, as manufacturing 
is not fully established, and a series of major concerns must be resolved in order to 
cover large mid- to long-term market requirements. Below is a brief summary of 
several relevant factors which must be addressed.
Production of HIV-derived vectors is a poorly optimized process, and a major 
hurdle to large-scale manufacturing is due in part to a deficient production of fully 
biologically active virions recovered in the culture media [19]. This is a dynamic 
process involving both production and inactivation rates, which ultimately renders 
on average 3–10 virus per producer cell [20], whereas during natural lentiviral 
infection, the number is close to 103/cell [21] and far removed from other vector 
systems such as AAV or Adenovirus, which render 104–105 viral particles per pro-
ducer cell. There are at least four major issues during production that can result in 
this poor yield: (a) transfection robustness, (b) protein interactions during mor-
phogenesis, (c) the nature of the cell system used for production, and (d) extremely 
labile essential components within the viral particles that lose activity during the 
production testing [22, 23].
3.1 DNA transfection
Production of HIV-derived lentivectors, and likewise other retroviral vectors 
derived from feline or equine Lentivirus or from gammaretroviruses, is based on 
DNA transfection of producer cells. The overall method was firstly demonstrated 
as feasible in pioneering research using poliovirus [24, 25], and it is based on the 
concept that the viral genome cloned in plasmids can recapitulate the genetic and 
morphogenetic instructions upon introduction in a eukaryotic cell in order to pro-
duce viral progeny. Early gene therapy studies developed a further step by splitting 
viral components in different plasmids, allowing the generation of non-replicative 
viral vectors as nonstructural/replication instructions which were no longer pack-
aged in the progeny. These systems are currently also used to produce AAV-derived 
vectors. The basis is that packaging signals acting in cis are encoded in discrete 
regions of the viral genome. By including those sequences in the transfer plasmid 
bearing the therapeutic/reporter gene, transgenes are encapsidated in the virions. 
All the accessory functions are expressed during production from the so-called 
helper plasmids but are not licensed for encapsidation, as they do not carry the 
packaging signals, nor are they encoded in the transfer plasmid. The current model 
of production on large or small scales is based on DNA transfection of three or four 
plasmids. For a full, detailed description of the plasmid used in the production of 
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HIV-derived vectors, see [8]. As a result, efficiency is compromised by the propor-
tion of cells transfected with the proper combination of plasmids, and indeed 
earlier second-generation production systems that use just three plasmids are more 
efficient in production [6].
3.2 Pseudotyping
Lentiviral vectors can be designed to carry heterologous envelope proteins. This 
pseudotyping allows the selective targeting of specific cells, conferring broader 
uses on the vector. Thus, lentivectors bearing RD114 [26], CD105 [27], and more 
recently measles virus [28] envelope glycoproteins, among others, have been 
described as conferring specific targeting in B cells, T cells, and hematopoietic 
stem cells, respectively. However, most of the lentivectors that have entered into 
the clinic and are commonly being used in research are pseudotyped with Vesicular 
stomatitis virus g protein (VSVg). There are two reasons for this. First, a wide num-
ber of different cell types are targeted by such an envelope, and second, it confers 
robustness on the viral particle during the purification stages [29].
However, the presence of the VSV receptor in the producer cell line contrib-
utes to diminishing the viral burden in the harvest [30]. Envelope proteins are 
membrane proteins that pass through the secretory pathway involving the endo-
plasmic reticulum cisternae and the Golgi apparatus, before they reach the plasma 
membrane, a system also used for the synthesis and recycling of the membrane 
receptors. Prevention of a premature encounter between ligand and receptor is 
mandatory, in order to increase the env protein available for the morphogenetic 
program. Indeed, the impact of this phenomenon has evolved in the natural infec-
tion of HIV. Vpu, an HIV accessory protein (see below), plays a dual role in the viral 
cycle, firstly by promoting egress in a cell-type-dependent manner and secondly 
by controlling the recircularization of envelope proteins during the synthesis 
and preventing premature binding of the HIV gp160 env protein with the CD4 
natural receptor during T-cell infection [31, 32]. To our knowledge no data has 
been published which accounts for the impact of such a process (autotransduc-
tion) during HIV-derived VSV-pseudotyped processes, but data obtained in our 
company indicate that this phenomenon is actually taking place in the producer cell. 
By specific quantitation of retrotranscribed RNA and integrated copies of cDNA 
in the producer cell, we have been able to quantitate that 30–50% loss of the actual 
viral particles produced are lost by reentering in the producer cell. Different lines 
are currently being developed at VIVEbiotech to minimize or fully prevent this 
phenomenon.
3.3 Helper functions
In the case of HIV, unlike to Gammaretrovirus, there is an array of six viral 
products collectively named accessory proteins. Their roles are different through-
out the viral life cycle. Some are related to controlling the innate/cellular immune 
response (vif), others modulate the adaptive immune response (nef), while others 
are mandatory for a fully regulated genetic program (tat, rev), morphogenesis and 
the egress (vpu), or viral infectivity (vif, nef).
HIV-derived vectors are produced in the absence of five of the six accessory 
proteins encoded by the wild-type virus: with the exception of rev, the other five 
are not expressed in helper plasmids. The rationale is to minimize the presence of 
viral sequences in the transfer plasmid, enabling safer vectors and minimizing the 
recombination between viral sequences in order to limit the risk of rescue of wild-
type virus during production. Tat protein was unnecessary within the design of 
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third-generation vectors, as no viral promoter was used in production. However, as 
has been demonstrated, the effect of those other accessory proteins is not negligible, 
and their function during vector production is controversial [31, 32].
3.4 Manufacturing virus from DNA
As described above DNA transfection is the current and unique manner to 
produce lentiviral vectors. Three major concerns must be considered about this 
approach:
• Efficiency. Transfection of four plasmids raises a few concerns that affect the 
reproducibility and efficacy [6]. Alternative procedures rely on the generation 
of stable producer cells bearing helper functions, limiting the transfection to 
just the transfer plasmid, which aids robustness and production yields. Different 
approaches for either constitutive or inducible systems have been designed [33], 
but in most cases low titers have been achieved. Toxicity of the VSV proteins has 
been cited as limiting more efficient systems.
• Quantity/quality. DNA, just like any other reagent employed in the manufactur-
ing process, requires identical strict compliance with GMP. The production of 
batches requires a certification of analysis that includes protein contamination, 
sterility, and the sequencing of all plasmids, both helper and transfer plasmids. 
These tests and the large amount of DNA required to scale-up the process require 
an improvement in cost-effective methods regarding quantity.
• Scalability. As mentioned above, several transfection procedures are currently 
available, but only two are relevant to large-scale manufacturing, whether using 
calcium phosphate and/or PEI (polyethylenimine) as matrixes to accomplish 
stable DNA complexes (currently proposed as methods for scale-up manufac-
turing). It is worth pointing out that to our knowledge there are no system-
atic studies addressing the relative efficiency of the two methods, taking into 
account not just vector yields but also cost-effectiveness and the impact on the 
cost of the production process.
4. Manufacturing Lentivirus: the VIVEbiotech approach
There are several excellent reviews on the specific steps during the manufacture 
of lentiviral vectors, the approaches to consider when scaling up and the critical 
points to consider for decision-making [13, 14, 34]. However, all of the processes 
must conciliate at least the next three considerations: (a) potency, meaning the 
capability of producing large quantities of vector; (b) robustness, i.e., highly repro-
ducible; and (c) versatility, as demand changes according to project needs.
Manufacturing follows a process of production, purification, and concentration. 
At every step, specific features of the lentiviral vectors must be taken into account. 
Critical concerns to be considered include:
1. Production. It is worth remembering that lentiviral vectors are enveloped, and 
both cellular proteins and lipid content can vary depending on the culture 
conditions [22]. As previously mentioned, pseudotyping is of major relevance, 
as it can affect the fate of the produced virions and also contribute to the 
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physical properties of the particles [35] and interaction with the solid phase in 
bioreactors.
2. Harvesting. It requires a consideration of the fact of interaction of the virions 
with the solid phase in bioreactors, in addition to the highly unstable nature 
of lentivectors, with their very short half-life [19], and a high dependence of 
biological activity on physical conditions and particle content [36–38].
3. Purification. It is critical for maintenance of the bona fide conditions of the 
genome and capsid, and unfortunately lentivectors are currently purified by 
chemically based procedures, such as ion-exchange chromatography, which 
significantly affect particle viability. To the author’s knowledge, there is no 
current industrial process for purification using affinity chromatography.
Herein is an overview of the manufacturing process developed at VIVEbiotech, 
which focuses on some of the critical steps. VIVEbiotech has obtained authorization 
from the European Medicines Agency (EMA) to provide cGMP batches of lentiviral 
vectors under the manufacturing process the company has fully developed (see 
Figure 1). VIVEbiotech is currently releasing batches of lentiviral vectors produced 
under these conditions to clients in EU and the USA. VIVEbiotech’s manufacture of 
lentivectors is based on the fixed-bed bioreactor iCELLis™ supplied by Pall. High 
compaction in the solid phase allows for a large culture surface, ranging from 0.53 
to 2.6 m2 (Nano™ configuration) in 1 liter disposable bioreactor, and is further 
scalable up to approximately 300 m2 (500 + ™ configuration) based on chroma-
tography principles. In the 1 liter small configuration, the carriers made of PET are 
fixed in a 40 mL chamber, and the process is monitored by probes controlling cell 
growth, and physical–chemical conditions are monitored by in-process BioXpert 
software. The harvest is collected by perfusion and purified by ion-exchange chro-
matography. It is then concentrated by tangential flow filtration, rendering a final 
concentration factor close to 300-fold and reaching a yield on a per-surface basis 
in accordance with market standards [39]. This process has been fully optimized in 
two remarkable steps:
Figure 1. 
Manufacturing process of lentiviral vectors optimized at VIVEbotech.
Systems Biology
8
• The seed train of producer HEK293T cells has been optimized in order to 
minimize the cell density of the seed. The conditions are the lowest standard 
achieved for other cell types which (i) allow growth with almost no operator 
intervention; minimizing the risk contamination, (ii) growth is fully monitored 
by the BioXpert program, ensuring constant, reliable growth conditions, and 
(iii) this has allowed us to shorten the process by a third.
• DNA transfection is based on DNA-calcium-phosphate precipitation, making 
our process highly reliable (close to 90% efficiency) and cost-effective, even 
under cGMP.
5. Challenging by numbers
As mentioned above, vector production is becoming a roadblock which is hitting 
gene therapy capabilities. Let us examine a few numbers in order to understand 
the size of the problem. So, what does lentivector-based gene therapy need to do in 
order to ensure it can be applied in the future? Lentiviral vectors for what? In their 
current design, lentivectors are capable of being used in the treatment of blood 
disorders, central nervous system disorders, immune therapy for certain cancers, 
and neurological conditions that can be treated with stem cells delivering a cargo 
of corrector genes. How can this be transformed into numbers? Certain state-
ments require understanding, before setting out the main points which need to be 
addressed.
Leaving aside the fact that for every condition treatable by gene therapy, the 
number of patients is highly variable; estimations can be made using a highly 
prevalent disease under phase III by bluebird bio (www.bluebird.com) such as 
beta-thalassemia/sickle-cell trait (SCT). According to NIH data, 1100 infants are 
born every year among the African American community, and more than 100,000 
individuals are estimated to have SCD in the USA; in Africa 15 million Africans 
are estimated to have SCD, and there are 200–300,000 affected births per year 
worldwide (https://www.ncbi.nlm.nih.gov/books/NBK1377/). Current conditions 
for transduction efficiently into hematopoietic stem cells require around >1 × 1010 
biologically active particles per vector dose per infant patient though these data can 
vary depending on specific features of each treatment. According to current stan-
dards of the manufacturing process to achieve such production, harvest produced 
from 2 square meters and equivalent to 4–6 liters of harvest per patient would need 
to be produced, representing a huge quantity of 10,000 liters per year to treat new 
infant cases in the USA for SCD. Current platforms of production and, significantly, 
purification procedures are not capable of addressing this situation.
6. Conclusions
Gene therapy is no longer an experimental approach to treat genetic diseases. 
Several medicine agencies worldwide have approved the commercialization of 
medicinal products based on viral vectors as intermediate medicinal products. This 
raises the need to manufacture large quantities of viral vectors under costly cGMP 
manufacturing environment. There are a limited number of pharmaceutical and 
biotechnology companies capable to manufacture and release lentiviral vectors 
of defined composition and quality control in quantities to attend the foreseeable 
market needs. Challenges for the development of more controlled and cost-effective 
manufacturing process have yet to be overcome. The complicated manufacturing 
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process needs to be simplified to promote standardization and yield products 
of increased defined composition. However, there are still open questions that 
arise from the system employed for production, principally related to the model 
of production based on DNA-transfected produced cells. Automatization of the 
manufacturing process is also required, in order to increase capabilities leading to 
an industrialization process. This will contribute to developing global manufactur-
ing processes for lentiviral vectors and help to establish the target product profile 
and quality attributes. In summary, efforts in modifying the current manufactur-
ing model of lentivectors are needed to facilitate the entry into commercialization 
stages.
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